- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT05226780
Étude d'extension pour évaluer à quel point le NBI-921352 est sûr et tolérable en tant que traitement d'appoint pour les sujets atteints de SCN8A-DEE
Une étude d'extension prospective, interventionnelle et active à long terme pour évaluer l'innocuité et la tolérabilité du NBI-921352 en tant que traitement d'appoint chez les sujets atteints du syndrome d'encéphalopathie développementale et épileptique SCN8A (SCN8A-DEE)
Extension study to evaluate how safe and tolerable the drug NBI-921352 is when used as adjunctive therapy in participants with SCN8A developmental and epileptic encephalopathy syndrome (SCN8A-DEE).
Aperçu de l'étude
Statut
Intervention / Traitement
Type d'étude
Inscription (Réel)
Phase
- Phase 2
Contacts et emplacements
Lieux d'étude
-
-
California
-
San Francisco, California, États-Unis, 94143
- UCSF Medical Center
-
-
District of Columbia
-
Washington D.C., District of Columbia, États-Unis, 20010
- Children's National Hospital
-
-
New York
-
Rochester, New York, États-Unis, 14642
- University of Rochester
-
-
Texas
-
Fort Worth, Texas, États-Unis, 76104
- Cook Children's Medical Center
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Key Inclusion Criteria:
For Participants Who Participated in NBI-921352-DEE2012:
- Written or oral pediatric assent from the participant and written informed consent from the participant's parent(s) or legal guardian(s) for pediatric participants and adult participants who are not capable of providing consent. Adult participant who are ≥18 years of age and capable of providing consent should sign an Informed Consent Form (ICF).
- Completed 16 weeks of treatment in Study NBI-921352-DEE2012.
- Continue to use a nocturnal alerting system or practice consistent with standards of care for the duration of the study.
- Have an adequate rescue medication regimen per the investigator's judgment in place for the duration of the study.
For Participants Who did not Participate in NBI-921352-DEE2012:
- Written or oral pediatric assent from the participant if deemed capable of providing assent and written informed consent from the participant's parent(s) or legal guardian(s) for pediatric participants and for adult participants who are not capable of providing consent. Adult participants who are capable of providing consent should sign an ICF.
- Be a male or female 2 to 21 years of age, inclusive.
- Have a diagnosis of SCN8A-DEE supported by both clinical and genetic findings.
- Have on average at least 1 countable motor seizure per week and not be seizure-free for more than 20 consecutive days.
- Being treated with at least 1 other antiseizure medication (ASM), but no more than 4 ASMs.
- Have failed to achieve seizure freedom with at least 2 ASMs.
- Have a body weight of at least 10 kilograms.
Key Exclusion Criteria
For Participants Who Participated in NBI-921352-DEE2012:
- Have developed any other disorder for which the treatment takes priority over treatment of SCN8A-DEE or is likely to interfere with study treatment or impair treatment compliance.
For Participants Who did not Participate in NBI-921352-DEE2012:
- Have symptoms that would be more consistent with another epilepsy disorder such as Dravet syndrome (for example, fever-induced episodes of status epilepticus, frequent myoclonic seizures, worsening on sodium channel blockers, absence seizures with generalized spike-and-wave electroencephalogram [EEG] as the sole seizure type).
- Currently receiving cannabinoids or medical marijuana except Epidiolex/Epidyolex, unless approved by the Sponsor.
- Currently taking systemic steroids (excluding inhaled medication for asthma treatments and intranasal steroids for allergies) such as adrenocorticotropin hormone, high-dose prednisolone for epileptic spasms. If participant has received these medications in the past, they must be off these medications for at least 3 months prior to the screening visit and these drugs may not be initiated during the duration of the study. Intermittent steroids to treat non-epilepsy-related diseases (such as allergies or dermatological conditions) are not exclusionary.
- Have a history of moderate or severe head trauma or other neurological disorders or systemic medical diseases that are, in the investigator's opinion, likely to affect nervous system functioning.
- Have a clinically significant medical condition or chronic disease, that in the opinion of the investigator would preclude the participant from participating in and completing the study or that could confound interpretation of study outcome.
- Have clinically significant abnormal vital signs at the screening visit, as determined by the investigator.
- Have one or more clinical laboratory test values outside the reference range, based on blood samples taken at the screening visit, that are of potential risk to the participants safety as determined by the investigator.
- Have, at the screening visit, an electrocardiogram (ECG) finding of a corrected QT interval using Fridericia's formula (QTcF) > 450 milliseconds (msec) or presence of any significant cardiac abnormality.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: NBI-921352
NBI-921352 administered for up to 164 weeks. |
Administered orally |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Délai |
|---|---|
|
Number of Participants with Serious treatment-emergent adverse events (TEAEs), TEAEs Leading to Discontinuation and Fatal TEAEs
Délai: Day 1 to Week 168
|
Day 1 to Week 168
|
Mesures de résultats secondaires
Mesure des résultats |
Délai |
|---|---|
|
Percentage Change from Baseline in 28-day Seizure Frequency for Countable Motor Seizures
Délai: Baseline, up to Week 162
|
Baseline, up to Week 162
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Directeur d'études: Clinical Development Lead, Neurocrine Biosciences
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- NBI-921352-DEE2013
- 2021-004393-62 (Numéro EudraCT)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .